EGFR was overexpressed in metaplastic breast cancer, and EGFR inhibitor was potential therapeutic agent for metaplastic breast cancer with 7p11.2 amplification (Reis-Filho et al., 2006). Here, EGFR is linked to metaplastic breast carcinoma.